LENZ vs STAA
LENZ: LENZ Therapeutics is a commercial-stage ophthalmic company that developed VIZZ, the first FDA-approved, once-daily aceclidine-based eye drop for the treatment of presbyopia. STAA: STAAR Surgical designs and manufactures implantable collamer lenses (ICLs) for refractive vision correction, offering reversible alternatives to corneal refractive surgery.
Side-by-side fundamentals
| Metric | LENZ | STAA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.34 | $24.71 | |
| Market cap as of 2026-07-23 | $167M | $1.2B | |
| PEG as of 2026-07-23 | -0.01 | n/a | |
| Net margin as of 2026-07-23 | -519.3% | -7.2% | STAA higher |
| Gross margin as of 2026-07-23 | +97.8% | +76.9% | LENZ higher |
| Operating margin as of 2026-07-23 | -563.8% | -9.1% | STAA higher |
| ROE as of 2026-07-23 | -37.6% | -6.1% | STAA higher |
| ROA as of 2026-07-23 | -34.8% | -4.7% | STAA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +4.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +0.0% | |
| Beta as of 2026-07-23 | 2.07 | 1.23 | |
| 1-year return as of 2026-07-22 close | -84.6% | +35.2% | STAA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.